Eli Lilly gets FDA EUA status for bamlanivimab to treat Covid-19

This article was originally published here

The EUA status enables to use bamlanivimab 700 mg to treat mild to moderate Covid-19 in adults and paediatric patients aged 12 years and older with a positive

The post Eli Lilly gets FDA EUA status for bamlanivimab to treat Covid-19 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply